Trial Profile
A real-world risk analysis of adalimumab and etanercept in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary)
- Indications Liver disorders; Tuberculosis
- Focus Adverse reactions
- 06 Sep 2017 New trial record